Challenging the Government Analyst Report in Delhi NSQ Cases: A Practitioner's Guide

In over 14 years of exclusive drug and cosmetics law practice at the Delhi High Court, Advocate Srijan Tiwari has handled hundreds of NSQ (Not of Standard Quality) prosecution matters. The most consistent lesson across all of them: the government analyst's report — Form 29 under the Drugs and Cosmetics Rules, 1945 — is rarely unassailable. The five categories of challenge outlined in this practitioner's guide have collectively secured outcomes ranging from discharge orders to acquittals for pharmaceutical corporation clients.

The Legal Significance of Form 29

Form 29 is the Government Analyst's Report — the formal document in which the government analyst records the results of their analysis of a drug sample and declares whether it conforms to the standard quality as specified in the Drugs and Cosmetics Act and Rules. It is the foundational document of an NSQ prosecution.

Under Section 25 of the Drugs and Cosmetics Act, a Form 29 report issued by a government analyst is admissible as evidence of the facts stated in it. This creates a presumption in favour of the prosecution — but it is a rebuttable presumption. Advocate Srijan Tiwari's practice is built on identifying and exploiting the grounds on which this presumption can be rebutted.

Critically, the accused company has the right to require the government analyst to appear before the court for cross-examination. This right — if exercised strategically — opens up all five categories of challenge described below.

Challenge 1: The Analyst's Qualification Is Deficient or Unproven

Under Rule 44 of the Drugs and Cosmetics Rules, a government analyst must possess specific educational qualifications and experience in drug analysis. These requirements are not merely administrative — they go to the competence of the analyst to issue a valid NSQ report.

The challenge Advocate Srijan Tiwari deploys in this category is twofold. First, a Right to Information (RTI) application is filed with the relevant state drug authority requesting the qualification documents and appointment order of the specific analyst who signed Form 29. Second, if cross-examination reveals that the analyst lacks the required qualifications — or if the prosecution fails to prove them — Advocate Srijan Tiwari argues that the analyst was not a "government analyst" as defined under the Act, and therefore Form 29 issued by them is not admissible evidence.

This argument has succeeded before Delhi courts — both at the trial level and at the Delhi High Court — in multiple matters. It is a threshold challenge that can end the prosecution before any evidence on the merits of the quality failure is even considered.

Challenge 2: The Testing Methodology Was Not Pharmacopoeially Correct

Drug quality standards in India are prescribed in pharmacopoeias — primarily the Indian Pharmacopoeia (IP) and, where the IP is silent, the British Pharmacopoeia (BP) or United States Pharmacopeia (USP). The Drugs and Cosmetics Act requires that government analysts test drugs using the testing methods specified in the applicable pharmacopoeia.

In practice, Advocate Srijan Tiwari has found that government laboratory analysts frequently deviate from pharmacopoeial testing methods — using older methods, modified methods, or HPLC instruments with different specifications than those specified in the IP. These deviations, when exposed through cross-examination of the analyst, can render the Form 29 report unreliable.

This challenge requires significant technical expertise. Advocate Srijan Tiwari regularly works with pharmaceutical scientists and analysts to identify pharmacopoeial deviations in the government analyst's methodology — and then translates these technical deficiencies into legal arguments before the court. This intersection of scientific knowledge and legal strategy is a hallmark of the kind of specialised practice that NSQ defence demands.

Challenge 3: The Standard Applied Was Wrong or Outdated

Drug quality standards in India are dynamic — they are updated through official amendments to the Indian Pharmacopoeia and through specific notifications from the Ministry of Health. A drug batch manufactured at a given time is judged against the standards applicable at the time of manufacture — not standards that came into force subsequently.

In several matters handled by Advocate Srijan Tiwari, the government analyst applied a quality standard that was not the applicable standard for the drug's IP edition at the time of manufacture. This mismatch between the applied standard and the correct applicable standard goes to the validity of the NSQ finding — because the drug may well have conformed to the correct applicable standard.

Additionally, some government analysts have been found to apply quality standards prescribed for a different grade of the same drug — for example, applying API-grade standards to a finished formulation. This error can be exposed through careful reading of the Form 29 report against the relevant pharmacopoeia entry.

Challenge 4: The Sample Was Tested Beyond Its Shelf Life

Drugs have shelf lives — and testing a drug beyond its expiry date is not a reliable indicator of its quality at the time it was manufactured or when it was in circulation. This challenge is particularly powerful in cases where:

• The drug sample was collected close to its expiry date
• Significant time elapsed between sampling and testing (due to laboratory backlog)
• The drug was a temperature-sensitive formulation and cold chain compliance in transport to the laboratory is uncertain

Advocate Srijan Tiwari regularly builds this argument by examining the date of manufacture (from the product label), the date of sampling (from Form 22), and the date of testing (from Form 29) — and demonstrating to the court that any quality degradation observed may well be due to the passage of time rather than a manufacturing defect.

Where the drug has actually expired before the Form 29 report was issued, the argument is even stronger: quality testing of an expired drug is inherently unreliable and cannot form the basis of a prosecution for a manufacturing defect.

Challenge 5: The CDL Counter-Analysis Contradicts Form 29

The fifth and most powerful challenge in Advocate Srijan Tiwari's NSQ defence toolkit is obtaining a counter-analysis from the Central Drugs Laboratory (CDL) in Kolkata. The CDL is India's national reference laboratory — its findings carry the highest evidentiary weight in Indian drug law proceedings.

Under Section 25(3) of the Drugs and Cosmetics Act, an accused company can request that the retained sample of the drug (held by the state drug authority) be sent to the CDL for independent analysis. If the CDL's report finds that the drug conforms to quality standards — contradicting the state government analyst's Form 29 — this creates a conflict in evidence that the prosecution must resolve.

Courts have consistently held that where the CDL and the state government analyst's reports conflict, the CDL report carries greater weight — and the benefit of doubt goes to the accused manufacturer. Advocate Srijan Tiwari has secured complete dismissal of NSQ prosecutions based on this outcome, including in matters before the Delhi High Court.

Timing is critical: the CDL counter-analysis application must be filed before the retained sample expires. Advocate Srijan Tiwari files this application as a matter of routine in every new NSQ mandate — because even where the CDL application is ultimately not needed (if the case resolves on other grounds), preserving the option is always essential.

The Combined Defence Strategy

In practice, Advocate Srijan Tiwari deploys these five challenges in combination — not in isolation. The analyst qualification challenge works as a threshold jurisdictional argument; the testing methodology and standard challenges work as merits-based technical challenges; the shelf life challenge works as a causation argument (undermining the link between any quality failure and manufacturing defect); and the CDL counter-analysis works as the positive evidence that the drug actually conformed to standards.

This multi-layered approach maximises the chances of a favourable outcome — because even if one challenge fails, the others remain. It also demonstrates to the prosecution and the court that the defence has thoroughly prepared — which often leads the prosecution to re-evaluate its position and, in some cases, compound the matter rather than proceed to a full trial.

For pharmaceutical corporations facing NSQ prosecution at Delhi courts — contact Advocate Srijan Tiwari immediately: 9899966225 | srijantiwari@hotmail.com | Delhi High Court